Back to Search
Start Over
Steps to redressing an imbalance: GLP-1 analogues for obesity in east Asia.
- Source :
-
The lancet. Diabetes & endocrinology [Lancet Diabetes Endocrinol] 2022 Mar; Vol. 10 (3), pp. 153-154. Date of Electronic Publication: 2022 Feb 04. - Publication Year :
- 2022
-
Abstract
- Competing Interests: TM-MT was supported by research funding from the UK National Institute for Health Research (NIHR), NIHR Imperial Biomedical Research Centre, JP Moulton Charitable Foundation, and Leadiant Pharmaceuticals; and is a consultant for and shareholder in Zihipp, a company that develops gut hormone analogues of GLP-1, oxyntomodulin, glucose-dependent insulinotropic peptide, and peptide YY for obesity and diabetes. BK declares no competing interests.
Details
- Language :
- English
- ISSN :
- 2213-8595
- Volume :
- 10
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- The lancet. Diabetes & endocrinology
- Publication Type :
- Academic Journal
- Accession number :
- 35131036
- Full Text :
- https://doi.org/10.1016/S2213-8587(22)00038-9